Close Menu

NEW YORK ─ Amoy Diagnostics of Xiamen, China, said on Thursday that it has inked an agreement with Shanghai-based Haihe Pharmaceutical to codevelop a companion diagnostic test for the Japanese market.

The CDx, based on AmoyDx's PCR platform, is being developed for use with Haihe's MET kinase inhibitor Glumetinib (SCC244), which targets c-MET exon14 skipping alterations in patients with non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.